Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 207

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 207
---

will be made based primarily on products approaching expiry period and forecasts of product demand. The excess balance above the product
demand as determined by this analysis becomes the basis for excess inventory charge and the written-down value of the inventory becomes
its cost. Written-down inventory would not be reversed if market conditions improve.

Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.

Convertible Instruments are
categorized as equity or debt based on the terms of the notes. Convertible Notes are recorded at amounts equal to the proceeds of the
issuance, including the embedded conversion feature, and net of discounts and unamortized debt issuance in accordance with ASC 480-10-55-44
on the consolidated balance sheets. An evaluation of all conversion, purchase and redemption features contained in a debt instrument is
performed to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is recorded
separately as a derivative liability at its fair value, calculated using the Black-Scholes model.

Debt issuance and offering
costs are amortized over the contractual term of the Convertible Notes, to the consolidated statements of operations in accordance with
ASC 835-30-45-1A.

The convertible notes are
subsequently recorded at amortized cost, with interest expense recognized using the effective interest method. The derivative liability,
if any is remeasured at fair value at each reporting date and any gain or loss on fair value is recognized in the statement of comprehensive
income.

Promissory notes, originated
from ASCA’s transaction and being taken over by NewGenIVF Group Limited upon merger, are of non-interest bearing and recorded at
original cost. They are subsequently measured at amortised cost, with interest expense recognized using the effective interest method
in the consolidated statement of income.

<div align='center'>F-14</div>

The Company’s ordinary
shares are stated at no par value. The difference between the consideration received, net of issuance cost, is recorded in additional
paid-in capital.

On January 21, 2025, the
Board of Directors of the Company approved a reverse stock split of all of the Company’s issued and unissued shares, including the